Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) (ROSY-T)

Trial Identifier: D5161N00007
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT05629234
Start Date: May 2023
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586
MY Kuching, MY, 93586